Hep C Gilead registry (no SVR)

This Registry study will enroll subjects who did not achieve a sustained virologic response after receiving at least one oral antiviral agent (OAV) while participating in a Gilead-sponsored hepatitis C clinical trial. For this current trial, patients who complete treatment with GS-7977 and fail to achieve a sustained virologic response, as defined by the protocol, will be asked to provide ongoing follow-up for three additional years. Once enrolled, participants will be followed for up to 3 years. Visits will occur at Baseline and Weeks 24, 48, 72, 96, 120 and 144. At each visit, subjects will have blood drawn and a quality of life survey will be completed.